SBER 320.62 ₽ -0.52% ROSN 387.60 ₽ -0.39% LKOH 4 880 ₽ -1.96% NVTK 1 075 ₽ +0.71% PLZL 2 090 ₽ -0.58% GAZP 115.64 ₽ -0.05% SIBN 501.45 ₽ -0.92% GMKN 126.38 ₽ +0.60% YDEX 4 014 ₽ +0.04% TATN 602.10 ₽ -1.15% VTBR 79.15 ₽ +0.19% OZON 3 995 ₽ -0.76% PHOR 6 385 ₽ +0.03% GAZT 1 739 ₽ +0.00% T 301.46 ₽ -0.23% AKRN 18 350 ₽ +0.11% SNGS 18.73 ₽ -0.45% X5 2 446 ₽ -0.04% CHMF 688.60 ₽ -0.35% RUAL 34.44 ₽ +1.10% NLMK 79.30 ₽ -0.75% MTSS 228.10 ₽ -0.24% DOMRF 2 414 ₽ +0.34% MOEX 175.27 ₽ +0.09% ESGE 75.95 ₽ -0.12% FMMM 13.31 ₽ +0.09% GOLD 2.63 ₽ +1.07% SBHI 6.88 ₽ -0.95% TLCB 9.57 ₽ +0.10% TMOS 6.15 ₽ -0.16% BCSR 10.91 ₽ -0.27% INGO 161.90 ₽ -0.18% AKFB 134.85 ₽ +0.07% AKBC 95.90 ₽ -0.31% AKQU 69.90 ₽ -0.72% AMGB 133.10 ₽ +0.15% SU26245RMFS9 88.31 ₽ -0.10% SU26246RMFS7 87.99 ₽ -0.15% SU26244RMFS2 86.47 ₽ -0.05% SU29022RMFS9 97.10 ₽ +0.15% SU29023RMFS7 96.83 ₽ +0.05% SU29026RMFS0 96.40 ₽ -0.02% SU29027RMFS8 96.10 ₽ -0.04% SU29028RMFS6 95.24 ₽ +0.05% SU29029RMFS4 94.92 ₽ -0.01% SU26252RMFS5 92.49 ₽ -0.12% SU26254RMFS1 92.15 ₽ -0.10% SU26249RMFS1 88.42 ₽ -0.09% SiM6 71 515 ₽ -0.64% SiU6 72 550 ₽ -0.60% EuM6 83 355 ₽ -0.48% EuU6 84 323 ₽ -0.45% FSM6 5 876 ₽ -0.36% SiZ6 74 482 ₽ -0.52% IRM6 28 883 ₽ -0.25% HSM6 25 895 ₽ +0.87% SRM6 32 313 ₽ -0.64% FSU6 6 100 ₽ +0.35% GZM6 11 657 ₽ -0.11% UNM6 12 977 ₽ -1.02% SBER 320.62 ₽ -0.52% ROSN 387.60 ₽ -0.39% LKOH 4 880 ₽ -1.96% NVTK 1 075 ₽ +0.71% PLZL 2 090 ₽ -0.58% GAZP 115.64 ₽ -0.05% SIBN 501.45 ₽ -0.92% GMKN 126.38 ₽ +0.60% YDEX 4 014 ₽ +0.04% TATN 602.10 ₽ -1.15% VTBR 79.15 ₽ +0.19% OZON 3 995 ₽ -0.76% PHOR 6 385 ₽ +0.03% GAZT 1 739 ₽ +0.00% T 301.46 ₽ -0.23% AKRN 18 350 ₽ +0.11% SNGS 18.73 ₽ -0.45% X5 2 446 ₽ -0.04% CHMF 688.60 ₽ -0.35% RUAL 34.44 ₽ +1.10% NLMK 79.30 ₽ -0.75% MTSS 228.10 ₽ -0.24% DOMRF 2 414 ₽ +0.34% MOEX 175.27 ₽ +0.09% ESGE 75.95 ₽ -0.12% FMMM 13.31 ₽ +0.09% GOLD 2.63 ₽ +1.07% SBHI 6.88 ₽ -0.95% TLCB 9.57 ₽ +0.10% TMOS 6.15 ₽ -0.16% BCSR 10.91 ₽ -0.27% INGO 161.90 ₽ -0.18% AKFB 134.85 ₽ +0.07% AKBC 95.90 ₽ -0.31% AKQU 69.90 ₽ -0.72% AMGB 133.10 ₽ +0.15% SU26245RMFS9 88.31 ₽ -0.10% SU26246RMFS7 87.99 ₽ -0.15% SU26244RMFS2 86.47 ₽ -0.05% SU29022RMFS9 97.10 ₽ +0.15% SU29023RMFS7 96.83 ₽ +0.05% SU29026RMFS0 96.40 ₽ -0.02% SU29027RMFS8 96.10 ₽ -0.04% SU29028RMFS6 95.24 ₽ +0.05% SU29029RMFS4 94.92 ₽ -0.01% SU26252RMFS5 92.49 ₽ -0.12% SU26254RMFS1 92.15 ₽ -0.10% SU26249RMFS1 88.42 ₽ -0.09% SiM6 71 515 ₽ -0.64% SiU6 72 550 ₽ -0.60% EuM6 83 355 ₽ -0.48% EuU6 84 323 ₽ -0.45% FSM6 5 876 ₽ -0.36% SiZ6 74 482 ₽ -0.52% IRM6 28 883 ₽ -0.25% HSM6 25 895 ₽ +0.87% SRM6 32 313 ₽ -0.64% FSU6 6 100 ₽ +0.35% GZM6 11 657 ₽ -0.11% UNM6 12 977 ₽ -1.02% SBER 320.62 ₽ -0.52% ROSN 387.60 ₽ -0.39% LKOH 4 880 ₽ -1.96% NVTK 1 075 ₽ +0.71% PLZL 2 090 ₽ -0.58% GAZP 115.64 ₽ -0.05% SIBN 501.45 ₽ -0.92% GMKN 126.38 ₽ +0.60% YDEX 4 014 ₽ +0.04% TATN 602.10 ₽ -1.15% VTBR 79.15 ₽ +0.19% OZON 3 995 ₽ -0.76% PHOR 6 385 ₽ +0.03% GAZT 1 739 ₽ +0.00% T 301.46 ₽ -0.23% AKRN 18 350 ₽ +0.11% SNGS 18.73 ₽ -0.45% X5 2 446 ₽ -0.04% CHMF 688.60 ₽ -0.35% RUAL 34.44 ₽ +1.10% NLMK 79.30 ₽ -0.75% MTSS 228.10 ₽ -0.24% DOMRF 2 414 ₽ +0.34% MOEX 175.27 ₽ +0.09% ESGE 75.95 ₽ -0.12% FMMM 13.31 ₽ +0.09% GOLD 2.63 ₽ +1.07% SBHI 6.88 ₽ -0.95% TLCB 9.57 ₽ +0.10% TMOS 6.15 ₽ -0.16% BCSR 10.91 ₽ -0.27% INGO 161.90 ₽ -0.18% AKFB 134.85 ₽ +0.07% AKBC 95.90 ₽ -0.31% AKQU 69.90 ₽ -0.72% AMGB 133.10 ₽ +0.15% SU26245RMFS9 88.31 ₽ -0.10% SU26246RMFS7 87.99 ₽ -0.15% SU26244RMFS2 86.47 ₽ -0.05% SU29022RMFS9 97.10 ₽ +0.15% SU29023RMFS7 96.83 ₽ +0.05% SU29026RMFS0 96.40 ₽ -0.02% SU29027RMFS8 96.10 ₽ -0.04% SU29028RMFS6 95.24 ₽ +0.05% SU29029RMFS4 94.92 ₽ -0.01% SU26252RMFS5 92.49 ₽ -0.12% SU26254RMFS1 92.15 ₽ -0.10% SU26249RMFS1 88.42 ₽ -0.09% SiM6 71 515 ₽ -0.64% SiU6 72 550 ₽ -0.60% EuM6 83 355 ₽ -0.48% EuU6 84 323 ₽ -0.45% FSM6 5 876 ₽ -0.36% SiZ6 74 482 ₽ -0.52% IRM6 28 883 ₽ -0.25% HSM6 25 895 ₽ +0.87% SRM6 32 313 ₽ -0.64% FSU6 6 100 ₽ +0.35% GZM6 11 657 ₽ -0.11% UNM6 12 977 ₽ -1.02%
Все новости
ВАЖНО ▼ Негатив
4 д назад · 1 источник

РФ продлила 'Промомеду' право выпускать семаглутид без согласия Novo Nordisk на год

Правительство РФ продлило на год разрешение группе 'Промомед' на использование патентов Novo Nordisk для производства семаглутида. Это усилит конкуренцию для оригинального препарата.
#NVO фармацевтикапатентыдиабет
Интерфакс
Подробнее

Что говорят